

The Current Comparative Effectiveness Landscape: NIH Activities

Michael S Lauer, MD, FACC, FAHA

Director, Division of Cardiovascular Sciences
National Heart, Lung, and Blood Institute

Comparative Effectiveness Summit


Grand Hyatt, Washington DC

Disclosures: None


November 5, 2012



An NIH Success Story




“Yeah, But ...?”



“I recalled how I had helped get an access road built to his farm, how I had visited him in a military hospital, how I had..., how I had...”


Telling a Landscape Story



http://qed.princeton.edu/getfile.php?f=Minard_carte_figurative.jpg

A “Credible” Science Landscape Story


Cycle of Credibility



Money

Börner, Katy. *Atlas of Science: Visualizing What We Know*. (2010). The MIT Press. Pg 59.

The Ecology of Biomedical Research



Growth from 1994 to 2003: 7.8%

Growth from 2003 to 2008: 3.4%

Percent of total health costs: 4.5%


Percent on health services research: 0.1%

Major sources:


Industry: 58%

Federal: 33%


NIH Research




Research Project Grants Applications, Awards, and Success Rates




The NIH Landscape (Map)




The NIH Landscape (Map)



NIH CER in 2012 (\$490 Million, 592 Projects)



Zoom in for a Closer Look



Even Closer

coronary
myocardial_infarction
coronary_artery



5U01HL105907-02 (2012)
PI: HOCHMAN, JUDITH S
The Ischemia Trial - CCC

[Highlight](#) [Retrieve Similar](#) [Limit to Similar](#) [Show More](#)

treatment
randomized_controlled

Something Completely Different

3U10HD055944-03S1 (Supplement, 2009)
PI: CASSON, PETER R
Metformin Use During in Vitro Fertilization in Polycystic Ovary Syndrome

Highlight Retrieve Similar Limit to Similar Show More

Cell Biology

Developmental Neuroscience

Integrative, Functional, & Cognitive Neuroscience

Comparative

NIH Institute

NCI

NIDDK

NIDA

NIH

rt Da

e Ma

ers

Show Me More

3U10HD055944-03S1 (Supplement, 2009)
PI: CASSON, PETER R
Metformin Use During in Vitro Fertilization in Polycystic Ovary Syndrome

[Highlight](#) [Retrieve Similar](#) [Limit to Similar](#)

Abstract:

established, continued metformin use will reduce the rate of embryonic loss, as well as adverse obstetric outcomes later in gestation. To address this issue, this application proposes a 500 subject multicenter, three arm, and randomized, blinded clinical trial, giving metformin both for 3 months prior and during the IVF cycle, and assessing oocyte and embryo quality. Further, the proposal continues the metformin or placebo through the first 12 weeks of gestation to assess the potential beneficial effect reducing embryonic loss. If this hypothesis is proven true, metformin administration at IVF would represent a novel and

Topics:

- 22.69 embryos oocyte oocytes egg embryo sperm maturation fertilization mo
- 12.61 network recruitment consortium center clinical_research multicenter cen
- 12.61 design optimal re limitations overcome optimization optimize optimize

[Full Page](#) [NIH RePORTer](#) [Show Less](#)

Output So Far

NIH RePORTER - NIH Research ...

NATIONAL INSTITUTES OF HEALTH
Research Portfolio Online Reporting Tools (RePORT)
REPORTS, DATA AND ANALYSES OF NIH RESEARCH ACTIVITIES

Search

HOME | ABOUT RePORT | FAQs | GLOSSARY | CONTACT US

QUICK LINKS | RESEARCH | ORGANIZATIONS | WORKFORCE | FUNDING | REPORTS | LINKS & DATA

Home > RePORTER > Project Information

MyRePORTER Login | Register System Health: GREEN

Project Information

3U10HD055944-03S1

Back to Query Form Print Version

DESCRIPTION | DETAILS | RESULTS | HISTORY | SUBPROJECTS | SIMILAR PROJECTS | NEARBY PROJECTS BETA | LINKS | NEWS AND MORE

Project Number: 3U10HD055944-03S1
Title: METFORMIN USE DURING IN VITRO FERTILIZATION IN POLYCYSTIC OVARY SYNDROME
Contact PI / Project Leader: [CASSON, PETER R](#)
Awardee Organization: UNIVERSITY OF VERMONT & ST AGRIC COLLEGE

ABOUT RePORTER RESULTS
Publications: [Publications missing?](#) [Principal Investigators](#) [click here](#)
Click on the column header to sort the results


Page 1 of 1

= PubMed = PubMed Central = Google Scholar [EXPORT](#)

Title (Link to full-text in PubMed Central)	Journal (Link to PubMed abstract)	Authors	Similar Publications	Cited By
Altering hirsutism through ovulation induction in women with polycystic ovary syndrome.	Obstetrics and gynecology, 2012 Jun; 119 (6) :1151-6	Roth, Lauren W; Huang, Hao; Legro, Richard S; Diamond, Michael P; Coutifaris, Christos; Carson, Sandra A; Steinkamp, Michael P; Carr, Bruce R; McGovern, Peter G; Cataldo, Nicholas A; Gosman, Gabriella G; Nestler, John E; Myers, Evan R; Zhang, Heping; Schlaff, William D; Reproductive Medicine Network		
The Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial: rationale and design of a double-blind randomized	Contemporary clinical trials, 2012 May; 33 (3) :470-81	Legro, Richard S; Kunselman, Allen R; Brzyski, Robert G; Casson, Peter R; Diamond, Michael P; Schlaff, William D;		

A “Credible” Science Landscape Story

Cycle of Credibility



Data

Börner, Katy. *Atlas of Science: Visualizing What We Know*. (2010). The MIT Press. Pg 59.

Data on Diagnostics and Therapeutics

JAMA[®]

Use of Diagnostic Imaging Studies and Associated Radiation Exposure for Patients Enrolled in Large Integrated Health Care Systems, 1996-2010

Rebecca Smith-Bindman, MD

Diana L. Miglioretti, PhD

Eric Johnson, MS

Context Use of diagnostic imaging has increased significantly within fee-for-service models of care. Little is known about patterns of imaging among members of large integrated health care systems.

Carboplatin and Paclitaxel With vs Without Bevacizumab in Older Patients With Advanced Non-Small Cell Lung Cancer

Junya Zhu, MS, MA


Dhruv B. Sharma, PhD

Stacy W. Gray, MD, AM


Aileen B. Chen, MD, MPP

Context A previous randomized trial demonstrated that adding bevacizumab to carboplatin and paclitaxel improved survival in advanced non-small cell lung cancer (NSCLC). However, longer survival was not observed in the subgroup of patients aged 65 years or older.

Data on Diagnostics (HMO RN)




Data on Therapeutics (SEER-CMS)



A “Credible” Science Landscape Story

Articles



Börner, Katy. *Atlas of Science: Visualizing What We Know*. (2010). The MIT Press. Pg 59.


Control of Urinary Incontinence

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Anticholinergic Therapy vs. OnabotulinumtoxinA
for Urgency Urinary Incontinence

Funding:
NICHD
NIH-ORWH



Revascularization (NCDR, STS, CMS)

The NEW ENGLAND
JOURNAL of MEDICINE


ESTABLISHED IN 1812

APRIL 19, 2012

VOL. 366 NO. 16

Comparative Effectiveness of Revascularization Strategies

Funding:
NHLBI
ARRA-CER




Hot Off The Press!

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Strategies for Multivessel Revascularization in Patients with Diabetes

Funding:
NHLBI
Cordis
J and J
Boston Scientific
Eli Lilly
Sanofi-Aventis
BMS




Weight-Loss In Primary Care

The NEW ENGLAND
JOURNAL of MEDICINE

ESTABLISHED IN 1812 NOVEMBER 24, 2011 VOL. 365 NO. 21

Comparative Effectiveness of Weight-Loss Interventions
in Clinical Practice

Funding:
NHLBI



Treatment of Localized Prostate Cancer

The NEW ENGLAND
JOURNAL of MEDICINE


ESTABLISHED IN 1812

JULY 19, 2012

VOL. 367 NO. 3

Radical Prostatectomy versus Observation for Localized Prostate Cancer

Death from Any Cause



Funding:
VA
NCI
AHRQ


Clopidogrel in Recent Lacunar Stroke

The NEW ENGLAND JOURNAL of MEDICINE


ORIGINAL ARTICLE

Effects of Clopidogrel Added to Aspirin
in Patients with Recent Lacunar Stroke

Funding:
NINDS
Sanofi-Aventis
Bristol-Meyers
Squibb




A “Credible” Science Landscape Story



New Items

New Investigator-Initiated CER Applications



New RFA on Pragmatic Trials



Newly announced awards

Coordinating (Duke with others)
Health-care associated infections
Colon cancer screening
Suicide prevention
Lumbar imaging
Night-time antihypertensives
Chronic pain
Maintenance hemodialysis

Final Thoughts

- NIH CER activity “all over the map”
- Big data sources yield fruit
 - HMORN, CTSAs, SEER, CMS, registries
- Productivity: “Done a lot lately”
- Direction:
 - Digital data, integrated systems
 - Links (AHRQ, VA, CMS, FDA, PCORI, industry)
 - Practical trials, much lower costs

“There’s Lots Happening!”

“If all the seas were black ink, and the marshes were quills, and the heavens were parchments, and all the people were scribes...

...They would not suffice to record the depth of the government...”

-- Babylonian Talmud
(~1500 years ago)

Question Assumptions, Disrupt, Innovate



ING

